Boston Scientific has received the CE mark and initiated a limited market release of the fourth generation Vercise Genus Deep Brain Stimulation (DBS) system in Europe.
Hand-out Boston Scientific Corporation
Boston-Scientific-Corporation-Vercise-Genus-DBS-System
Featuring full-body MRI conditional and Bluetooth capabilities across the portfolio, the Vercise Genus System is indicated to treat the symptoms of Parkinson's disease, essential tremor, and dystonia by delivering precisely targeted electrical stimulation in the brain designed to provide optimal symptom relief.
Veerle Visser-Vandewalle, from Cologne University Hospital, Germany, said: "With neurodegenerative movement disorders, the ability to deliver the right dose of stimulation where it is needed can make a remarkable difference in controlling an individual patient's symptoms.”
Vercise Genus adds features for patients, including a low-profile two-in-one extension with the option of abdominal placement. New clinician software optimises programming with integrated visualisation using patient imaging via the company's relationship with Brainlab.
The fourth generation DBS system since 2012, Vercise Genus builds upon innovations such as multiple independent current control (MICC) and the cartesia directional lead with integrated visualisation.
Maulik Nanavaty, senior vice president and president, neuromodulation, Boston Scientific, said: "For patients, the Vercise Genus DBS System continues the tradition of small, thin devices, and it provides Bluetooth programming which is important during times of social distancing. Combined with the option of a 25-year rechargeable battery as well as the expanded MRI conditional feature available on our primary cell devices, patients can find the best option to suit their specific needs."
In Europe, the Vercise Genus DBS System is indicated for use in unilateral or bilateral stimulation of the subthalamic nucleus or internal globus pallidus for treatment of levodopa-responsive PD which is not adequately controlled with medication and for treatment of intractable primary and secondary Dystonia, for persons 7 years of age and older. Thalamic stimulation using the Vercise Genus DBS System is indicated for the suppression of tremor not adequately controlled by medications in patients diagnosed with essential tremor or PD.
